TOTAL VOLUME:
$134b
24H VOL:
$107,351,958
24H TRANSACTIONS:
2,388,728,490
OPEN INTEREST:
$1,416,970,024
400,720
Markets across
30,097
events
MATCHED EVENTS:
2,633
PLATFORM COVERAGE:
5
Polymarket:
39%
VS.
Kalshi:
61%
FDA approves Retatrutide this year?
- Polymarket
FDA approves Retatrutide this year? - Polymarket
1W
News
Positive
Negative
Neutral
Hover marker for details
Vol.
·
Resolves Jan 1, 2027
FDA approves Retatrutide this year?
$
Intro
This market tracks whether the U.S. Food and Drug Administration (FDA) will approve Eli Lilly’s retatrutide for any use before the end of 2026. Currently, Polymarket gives a 3.8% probability to the FDA approving retatrutide this year. The resolution source for this market will be official information from the FDA, with credible reporting used as supporting evidence. Keep an eye on potential updates following the Prescription Drug User Fee Act (PDUFA) target date for a potential decision, as this will signal key progress towards a possible approval or delay by January 1, 2027.
Polymarket
Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form If the listed drug is approved within this market’s timeframe, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Frequently asked questions
Currently, this market indicates a relatively low probability of FDA approval of Retatrutide this year. This contrasts with some analyst forecasts, which suggest a higher likelihood of approval based on recent clinical trial data. However, analyst predictions often don't fully incorporate the diverse perspectives and real-time information reflected in prediction market prices. It’s important to remember that prediction markets represent the collective wisdom of traders willing to put capital behind their beliefs, offering a unique signal compared to traditional expert opinions on this event.
On Polymarket, this market is priced through a continuous auction mechanism, where traders buy and sell shares representing their belief in the outcome. The price of a share directly reflects the implied probability of FDA approval this year. As more traders participate and new information becomes available, the price adjusts to reflect the evolving consensus. On Polymarket, prices reflect that venue's order book, liquidity, and how traders price the outcome right now. The current price indicates what percentage of the total market cap a share costs, and therefore the market's aggregate assessment of the approval likelihood.
This market resolves around Jan 1, 2027, with the outcome confirmed once the event is verifiable from credible public reporting. Resolution will depend on whether the FDA officially announces the approval of Retatrutide for any indication during the specified timeframe. The outcome will be based on publicly available information from the FDA and other reliable sources. Traders should monitor official announcements for clarity regarding the final resolution of this market.
Several key events could significantly impact this market. Positive or negative updates from the FDA regarding the review process for Retatrutide would be major catalysts. The release of further clinical trial data, particularly any safety concerns or efficacy improvements, could also shift the market. Unexpected regulatory delays or changes in the FDA’s stance on similar drugs could also influence trading activity. Any news related to competing treatments in the same therapeutic area could also affect the perceived value of Retatrutide and, therefore, the price in this market.
